Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study - Takeaways - MDSpire

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study

  • By

  • Gaurav Narula

  • Swaminathan Keerthivasagam

  • Hasmukh Jain

  • Sachin Punatar

  • Akanksha Chichra

  • Chetan Dhamne

  • Prashant Tembhare

  • Papagudi Ganesan Subramanian

  • Nikhil Patkar

  • Minal Poojary

  • Anant Gokarn

  • Sumeet Mirgh

  • Nishant Jindal

  • Albeena Nisar

  • Deepali Pandit

  • Khushali Pandit

  • Alka Dwivedi

  • Atharva Karulkar

  • Ankesh Kumar Jaiswal

  • Aalia Khan

  • Shreshtha Shah

  • Afrin Rafiq

  • Moumita Basu

  • Juber Pendhari

  • Sweety Asija

  • Ambalika Chowdury

  • Ankit Banik

  • Nirmalya Roy Moulik

  • Shyam Srinivasan

  • Shilpushp Bhosle

  • Sumathi Hiregoudar

  • Shashank Ojha

  • Lingaraj Nayak

  • Jayshree Thorat

  • Bhausaheb Bagal

  • Manju Sengar

  • Navin Khattry

  • Shripad Banavali

  • Steven Highfill

  • Nirali N. Shah

  • Rahul Purwar

  • April 24, 2025

  • 0 min

Share

  • 1

    The study focuses on a novel humanized CD19-CAR-T therapy, talicabtagene autoleucel, for pediatric patients with relapsed/refractory B-ALL.

  • 2

    Survival rates for pediatric B-ALL exceed 90% in developed countries, but outcomes for relapsed/refractory cases remain poor.

  • 3

    The pilot Phase 1 trial tested the safety and feasibility of HCAR-19 in patients aged 3-25 years, with a focus on dose optimization.

  • 4

    Regulatory approval for the trial involved multiple oversight bodies, highlighting the complexities of conducting gene therapy studies.

  • 5

    The study aims to improve access to CAR T-cell therapies in India, addressing the prohibitive costs that limit availability in low-income regions.

Original Source(s)

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study

  • by Gaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, Sachin Punatar, Akanksha Chichra, Chetan Dhamne, Prashant Tembhare, Papagudi Ganesan Subramanian, Nikhil Patkar, Minal Poojary, Anant Gokarn, Sumeet Mirgh, Nishant Jindal, Albeena Nisar, Deepali Pandit, Khushali Pandit, Alka Dwivedi, Atharva Karulkar, Ankesh Kumar Jaiswal, Aalia Khan, Shreshtha Shah, Afrin Rafiq, Moumita Basu, Juber Pendhari, Sweety Asija, Ambalika Chowdury, Ankit Banik, Nirmalya Roy Moulik, Shyam Srinivasan, Shilpushp Bhosle, Sumathi Hiregoudar, Shashank Ojha, Lingaraj Nayak, Jayshree Thorat, Bhausaheb Bagal, Manju Sengar, Navin Khattry, Shripad Banavali, Steven Highfill, Nirali N. Shah, Rahul Purwar

  • April 24, 2025

Related Content

Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases

Liver involvement in pediatric acute leukemia: subtype differences and complex hepatic injury as a novel marker for AML risk stratification

Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study